相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
终止
1
20.0%
Unknown
3
60.0%
撤回
1
20.0%
暂无批准数据
- A Northwestern Medicine study of over 18 million U.S. adults found the spring daylight saving time change was associated with up to a 30% increased risk of certain retinal vascular diseases in the following month. - Conditions affected included proliferative diabetic retinopathy and neovascular age-related macular degeneration, while the fall clock change showed a roughly 20% reduced risk for some retinal diseases. - Researchers suggest sleep loss and circadian disruption may trigger inflammation and metabolic changes that stress the retina's dense network of small blood vessels. - The observational study, published in Scientific Reports, cannot establish causation, and authors call for confirmation in larger databases with longer follow-up periods.
- Ischemic heart disease deaths in the U.S. fell by 58.7% from 1990 to 2023, driven largely by reductions in smoking and particulate air pollution, according to a JAMA Cardiology study. - Despite progress, 88.8% of the estimated 473,000 coronary artery disease deaths in 2023 were attributable to modifiable risk factors, led by high systolic blood pressure (47.2%), dietary risks (38.6%), and high LDL cholesterol (28.5%). - Deaths linked to high BMI and high fasting blood glucose have risen by 12.5% and 10.5% respectively since 1990, signaling growing challenges from obesity and diabetes. - Researchers and editorialists call for policy interventions, improved communication, and wider use of generic medicines to address the cardiovascular-kidney-metabolic syndrome and persistent geographic disparities.
- A Northwestern Medicine study reveals that radiotherapy fundamentally reshapes the immune ecosystem within cutaneous T-cell lymphoma (CTCL) tumors beyond simply killing cancer cells. - Researchers used spatial transcriptomics and a novel non-invasive skin tape-strip method to track molecular changes before and after radiotherapy in CTCL patients. - Tumors that recurred within one year showed increased radiation resistance genes and persistent inflammation, while remission tumors exhibited stronger interferon signaling and sustained humoral immune activation. - The findings open opportunities for combination therapies that enhance anti-tumor immunity and bring precision medicine closer to routine clinical care for CTCL.
- Endeavor Health Northwest Community Hospital received state approval for a $175 million, 104,000-square-foot cancer and neuroscience center in Arlington Heights, with construction expected to begin later this year and completion by December 2029. - Northwestern Medicine plans a $275 million cancer care facility in Orland Park, backed by a $225 million donation from the St. George Foundation, to replace the current St. George Cancer Institute. - Cancer incidence in the Northwest Community service area is projected to grow 12% between 2023 and 2028, while the CDC projects a 49% increase in annual cancer cases nationwide between 2015 and 2050. - The 70% five-year survival rate for cancer patients, up from approximately 50% in the mid-1970s, is driving increased demand for long-term outpatient cancer services across the Chicago region.
- Northwestern Medicine scientists identified a previously unrecognized regulatory axis—P-TEFb, BHLHE40, and Tim8-Tim13 complexes—that controls rapid gene expression changes during hypoxia, functioning partially independently of HIF. - The mechanism may explain why some treatment-resistant tumors respond poorly to HIF-targeted therapies, with particular relevance for clear cell renal cell carcinoma where hypoxia signaling is chronically activated. - The study, published in Science Advances, used proteomics, CRISPR gene editing, RNA interference, and ChIP-seq to characterize how cancer cells activate hypoxia-responsive genes beyond the well-known HIF pathway. - The findings uncover an unexpected link between mitochondria and nuclear gene regulation, highlighting new layers of complexity in how cells sense and respond to low oxygen.
- Northwestern Medicine researchers discovered that montelukast, a widely-used asthma medication, can restore immunotherapy sensitivity in treatment-resistant cancers by blocking the CysLTR1 receptor. - The study found that tumors hijack CysLTR1 to reprogram neutrophils into immunosuppressive cells, effectively shielding cancer from immune attack. - In preclinical models of triple-negative breast cancer and other aggressive cancers, montelukast slowed tumor growth and improved survival when combined with immunotherapy. - The findings offer particular significance for India, where approximately 100,000 women are diagnosed with triple-negative breast cancer annually and access to experimental therapies remains limited.
- Medtronic received FDA approval for its next-generation Mosaic Neo mitral bioprosthesis, designed for implantation through sternotomy, minimally invasive cardiac surgery, and robotic access. - The valve features enhanced design improvements including reduced left ventricular stent post protrusion, wide anterior distance between stent posts, and improved visualization under fluoroscopy. - Initial implants have been successfully performed at major U.S. hospitals, with the first robotic implantation and first concomitant use with Medtronic's Penditure LAA Exclusion System already completed. - Nearly 20,000 patients undergo surgical mitral valve replacement annually in the U.S., representing a significant market opportunity for this enhanced valve technology.
- Northwestern Medicine researchers identified that brain-resident microglia cells uniquely metabolize fructose through the GLUT5 transporter to suppress immune responses and promote glioblastoma tumor growth. - Removing the fructose transporter in mouse models prevented tumor growth entirely and activated cancer-killing CD8+ T-cells, suggesting a novel therapeutic target for brain cancer treatment. - The findings reveal that fructose acts differently in the brain compared to other organs, suppressing rather than promoting inflammation, opening new avenues for improving immunotherapy responses in glioblastoma patients.
- Tempus AI has formed strategic collaborations with Northwestern Medicine and NYU Langone Health to expand genomic testing access for cancer patients across all stages and types. - Northwestern Medicine will now offer next-generation sequencing to early-stage cancer patients, substantially augmenting their existing precision oncology capabilities. - NYU Langone Health partnership includes launching a prospective observational study for serial molecular profiling throughout patients' treatment journeys. - The collaborations aim to generate actionable insights for personalized cancer care through AI-powered predictive algorithms and biomarker discovery research.
- Northwestern Medicine and Scripps Health have enrolled their first patients in Aclarion's pivotal CLARITY trial, bringing the total number of active enrollment sites to four out of seven approved centers. - The multi-site trial aims to evaluate whether Nociscan technology can improve surgical outcomes beyond the current 54% industry benchmark for chronic low back pain surgery patients. - The company targets enrolling 25% of the planned 300 patients by Q2 2026, with initial interim data readout expected in Q3 2026 after the first cohort completes 3-month follow-up visits.
